In order to investigate the role of 18-hydroxy-11-deoxycorticosterone (18-OH-DOC) in essential hypertension (EH), the responses of plasma 18-OH-DOC to 7 stimulation tests (furosemide test, adrenal suppression test, angiotensin II infusion test, adrenal stimulation test, metopirone test, saline infusion test and potassium chloride infusion test) and the circadian rhythm were investigated in 18 patients with essential hypertension (low renin group : 8, and normal renin group : 10).
. Recently, novel steroids such as 16ƒÀ-hydroxydehydroepiandrosterone (Senett et al., 1975) , 18 -hydroxy-11-deoxycorticosterone (18-OH-DOC) (Melby et al., 1971 ) and 16, 18-dihydroxydeoxycorticosterone (Dale and Melby, 1974) have been implicated in the pathogenesis of EH, especially the type associated with a suppressed plasma renin activity (PRA).
With regard to 18-OH-DOC, several reports (Melby et al., 1971 ; Nowaczynski et al., 1975) have shown that the secretion rates of 18-OH-DOC and the urinary excretion of 18 -hydroxy-tetrahydro-deoxycorticosterone (18-OH-TH-DOC) were significantly higher in patients with EH and suppressed PRA. However, plasma levels of 18-OH-DOC in EH have not been investigated systematically. Therefore, we investigated the role of this steroid in EH, in order to further elucidate the abnomalities in steroid metabolism in EH.
Materials and Methods
All materials (Crystalline 18-OH-DOC, 1, 2-3H-18-OH-DOC, Solvents, Sephadex LH-20, Silica gel and Antiserum) were used as described previously (Den et al., 1977) .
The measurement of plasma levels of 18-OH-DOC was performed as described in the Den's paper (1977) Test procedures All subjects when studied were on a diet containing 5-8g NaCI, daily. Blood samples for baseline steroid determinations were drawn between 0800 and 0900 hr after overnight recumbency.
All hypertensive patients had been studied according to the following test procedures. 1) Circadian rhythm : Blood samples for circadian rhythm were drawn at 0600, 1600, and 2400 hr on recumbency. 2) Furosemide test : Immediately after the baseline sample was drawn, furosemide (0.7mg/kg) was administered intravenously and after 2 hr ambulation, another blood sample was collected.
3) Adrenal suppression test : One mg of dexamethasone was administered at 2100 hr orally, and on the next day, the baseline sample was drawn. Immediately afterwards, furosemide (0.7mg/kg) was administered intravenously, and after 2 hr ambulation, another blood sample was collected. 4) Angiotensin II infusion test : Immediately after the baseline sample was drawn between 1200 and 1300 hr, angiotensin II (8ng/kg/min., Hypertensin Ciba) was infused intravenously for 30min and plasma samples were collected 15, 30 and 45min later. 5) Adrenal stimulation test : Immediately after the baseline sample was drawn, a 4-hr infusion of 12.5 units of ACTH (Acthar, Armour Pharmaceutical Co.) in 500ml of 5% dextrose was begun, and two other samples were collected 2 and 4 hr later. The subjects remained recumbent throughout the study. 6) Metopirone test : One and half g of metopirone was administered at 2100 hr orally, and on the next morning, another plasma sample was drawn between 0800 and 0900 hr. 7) Saline infusion test : Immediately after the baseline sample was drawn, 1000ml of saline was infused for one hour and another blood sample was collected. 8) Potassium chloride infusion test : Immediately after the baseline sample was drawn, potassium chloride (0.3mEq/kg/min.) was infused intravenously for one hour and two other samples were collected 30 and 60min later. The subjects remained recumbent throughout the study. Plasma aldosterone and PRA were measured by the use of kit of LE COMMISSARIAT A L'ENERGIE ATOMIQUE, France.
Statistical comparisons were made by the use of Student's t test. (Melby et al., 1971; Nowaczynski et al., 1975) have reported some interesting results. But there are a few papers (Mason and Fraser, 1975; Chandler et al., 1976; Dale et al., 1976; Nakajima et al., 1977) about plasma levels of 18-OH-DOC and the results are contradictory and inconclusive.
Results
Up to now, Melby et al.(1971) reported the increased levels of the urinary excretion of 18-OH-DOC in only low renin EH. Nowaczynski et al.(1975) presented the increased secretion of 18-OH-DOC in EH with low and normal PRA.
However, studies of plasma levels of 18-OH-DOC in EH have not been performed systematically.
In the present studies, the levels of plasma 18-OH-DOC in circadian rhythm were slightly lower in patients with low PRA than in those with normal PRA. The discrepancy among the increased urinary excretion of 18-OH-DOC, the increased secretion of 18-OH-DOC and the low plasma levels of 18-OH-DOC would be due, at least to some extent, to the increased metabolic clearance rate of 18-OH-DOC or modifications in the circulating protein- In the responses of plasma levels of 18-OH-DOC after the administration of furosemide and 2-hr ambulation, there was no significant difference between these two groups. But some of patients with low or normal PRA showed the markedly increased responses to the test. Probably, these responses would be due to increased ACTH levels induced by 2 hr of ambulation. Furthermore, Dale et al. (1976) reported that the sensitivity of 18-OH-DOC to ACTH stimulation was more pronounced than that of other steroids.
In the study of adrenal suppression test, plasma levels of 18-OH-DOC after the treatement of dexamethasone decreased from baseline levels as shown in control subjects by Dale et al. (1976) .
In the furosemide test under dexamethasone, plasma levels of 18-OH-DOC were unchanged. From these results, it is possible that 18-OH-DOC was not increased by endogeneous angiotensin II induced by furosemide and 2 hr of ambulation. However, Nowaczynski et al. (1975) reported that the secretion rates of 18-OH-DOC increased after sodium deprivation in three healthy normotensive control subjects. Probably, this discrepancy between their and our results might depend on the difference in these both stimulation tests.
On the other hand, the infusion of exogenous angiotensin II induced the increased levels of 18-OH-DOC in patients with normal PRA, while the other group did not show the increased levels of 18-OH-DOC.
Recently, Nakajima et al. (1977) reported that angiotensin II infusion increased moderately plasma 18-OH-DOC in control subjects and the renin-angiotensin system played a minor role in the steroid secretion.
On the other hand, the responses of 18-OH-DOC to ACTH infusion in both groups were the same, and ACTH stimulation produced 20-fold increase in plasma concentration.
Furthermore, the responses of 18-OH-DOC after metopirone were similar in both groups.
In the study of plasma DOC levels to ACTH stimulation, we previously reported that patients with low PRA showed higher responses in plasma DOC levels after ACTH infusion than those with normal PRA . Therefore, it is suggested that plasma DOC and 18-OH-DOC in patients with low PRA were sensitive and not sensitive to angiotensin II, respectively, while those in patients with normal PRA were sensitive to ACTH as well as to angiotensin II.
In the experiments of saline infusion, the levels of 18-OH-DOC were decreased similarly in both groups as the circadian rhythm of cortisol. It may be concluded that 18-OH-DOC concentrations in patients with EH was not influenced by saline infusion.
In the study of potassium chloride infusion test, there was not any significant difference between 2 groups and there was no correlation betweeen 18-OH-DOC and PRA, serum K levels or aldosterone levels. Some of patients with EH showed the increased levels of 18-OH-DOC to potassium infusion. Through these results, it is suggested that a part of 18-OH-DOC may be temporarily secreted from adrenal by a stimulation of potassium chloride.
Finally, it might be thought that plasma 18-OH-DOC does not play an important role in the suppression of PRA in patients with low PRA from the present study. 
